BEIJING, July 22, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2016 financial results on Thursday, August 4, 2016 after the market closes.
The Company's management will hold a conference call at 7:30 a.m. ET on Friday, August 5, 2016, which is 7:30 p.m., Beijing Time on August 5, 2016, to discuss second quarter 2016 results. Listeners may access the call by dialing:
US: 1 888 346 8982
International: 1 412 902 4272
Hong Kong: 800 905 945
China: 400 120 1203
A telephone replay will be available one hour after the conclusion of the conference call through August 12, 2016. The dial-in details are:
US: 1 877 344 7529
International: 1 412 317 0088
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Email: [email protected]
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: [email protected]
SOURCE China Biologic Products, Inc.